secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031410
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q3 revenue $1.0M (down 52% QoQ), net loss $9.3M; engages Perella Weinburg for strategic alternatives
--------------------------------------------------------------------------------

- Total revenue $1.0M in Q3 2022 vs $2.1M prior quarter; net loss $9.3M ($0.08 per share) vs $13.8M loss ($0.15) in prior year.
- DetermaRx sample volume up 51% YoY; onboards physician base +62% YoY.
- Engaged Perella Weinburg Partners as advisor to evaluate strategic alternatives.
- Cash, equivalents, and marketable securities $34.2M as of Sept 30, 2022.
- DetermaIO sample volume from Early Adopters grew 117% QoQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/0001493152-22-031410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer